Clinical trial
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
NCT00345189 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00345189 |
|---|---|
| Title | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors |
| Official title | A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Lymphoma |
| Intervention type | Drug |
| Interventions | CNF2024 |
| Enrollment | 70 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Jun 27, 2006 |
| Last update posted | Jul 14, 2009 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: